Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Group A (people with cirrhosis, without suspected liver cancer):
- Adults aged 18 or older
- Enrolled in the French social security system
- Able to hold a conversation and read in French
- Willing and able to sign a consent form
- Diagnosed with a stable, well-managed form of liver scarring (cirrhosis), classified as Child-Pugh A, where a liver biopsy has been recommended as part of normal medical care
- Liver biopsy is being done to diagnose or confirm cirrhosis, or to find the cause of liver damage — and liver cancer is not suspected
Group B (people with cirrhosis, where liver cancer is suspected):
- Adults aged 18 or older
- Enrolled in the French social security system
- Able to hold a conversation and read in French
- Willing and able to sign a consent form
- Diagnosed with a stable, well-managed form of liver scarring (cirrhosis), classified as Child-Pugh A, where a liver biopsy has been recommended as part of normal medical care
- Liver biopsy is being done because imaging scans have raised suspicion of liver cancer (hepatocellular carcinoma)
Who may not be able to join:
- People with a personal history of any type of cancer, including liver cancer diagnosed before entering the study
- Women who are pregnant or breastfeeding
- Adults who are under a legal protection arrangement, such as guardianship or curatorship
- People for whom a standard liver biopsy procedure would not be safe, such as those with fluid build-up in the abdomen visible on scans or examination, blood clotting problems, blood-thinning medication that cannot be paused, or blocked bile ducts
- People who are currently detained by a court or government authority
- People who have an electronic implanted medical device, such as a pacemaker, implantable heart defibrillator, cochlear implant, or brain implant
- People with a psychotic disorder
- People with a degenerative neurological condition, such as Parkinson's disease, dementia, or Korsakoff's syndrome
- People taking certain heart rhythm medications, specifically those in drug classes known as Class Ia (such as Disopyramide or Quinidine) or Class Ic (such as Flecainide or Propafenone)
- People taking certain psychiatric medications that affect the nervous system, including specific antipsychotics (such as haloperidol, chlorpromazine, olanzapine, clozapine, or quetiapine) or tricyclic antidepressants (such as amitriptyline, amoxapine, or clomipramine) (confirm with trial site if unsure whether a current medication falls into these categories)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +33 4 26 73 27 33
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
RNA expression values encoding all adrenergic receptors, and all cholinergic receptors or subunits.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.